Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis

Audrey Payancé, Gilberto Silva‐Junior, Julien Bissonnette, Marion Tanguy, Blandine Pasquet, Cristina Levi, Olivier Roux, Ouardia Nekachtali, Anna Baiges, Virginia Hernández‐Gea, Cédric Laouénan, Didier Lebrec, Miguel Albuquerque, Valérie Paradis, Richard Moreau, Dominique Valla, François Durand, Chantal M. Boulanger, Juan‐Carlos Garcia‐Pagan, Pierre‐Emmanuel Rautou – 30 March 2018 – Microvesicles (MVs) are extracellular vesicles released by cells following activation or apoptosis. Some MV subpopulations augment with cirrhosis severity and contribute to portal hypertension.

The high burden of alcoholic cirrhosis in privately insured persons in the United States

Jessica L. Mellinger, Kerby Shedden, Gerald Scott Winder, Elliot Tapper, Megan Adams, Robert J Fontana, Michael L. Volk, Frederic C. Blow, Anna S.F. Lok – 26 March 2018 – Alcoholic cirrhosis (AC) is a major cause of liver‐related morbidity and mortality in the United States. Rising rates of alcohol use disorders in the United States will likely result in more alcoholic liver disease. Our aim was to determine the prevalence, health care use, and costs of AC among privately insured persons in the United States.

Loss of hypoxia inducible factor‐1α aggravates γδ T‐cell‐mediated inflammation during acetaminophen‐induced liver injury

Tomohiro Suzuki, Shoko Minagawa, Takashi Yamazaki, Takatomo Arai, Mai Kanai, Satoko Shinjo, Nobuhito Goda – 26 March 2018 – Acetaminophen (APAP)‐induced liver injury is closely associated with acute hepatic inflammation. Hypoxia‐inducible factor‐1 (HIF‐1) is activated during immunological processes and regulates gene expressions in various types of immune cells. Although HIF‐1 controls the differentiation and functions of conventional T cells in chronic inflammation, the pathological importance of HIF‐1 in innate‐like T cells during acute inflammation remains unknown.

Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis

Cyriel Y. Ponsioen, Keith D. Lindor, Ruby Mehta, Lara Dimick‐Santos – 25 March 2018 – Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease.

Subscribe to